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Actinic keratoses are common premalignant lesions that occur in fair-skinned individuals 
with high cumulative ultraviolet exposure. Monotherapy with ingenol mebutate has been 
known to cause local skin reactions, such as erythema, which reduces safety.  Clobetasol 
propionate has worked well with other actinic keratosis therapies to reduce inflammation, 
but its role with ingenol mebutate is not well understood.  The effect of concurrent 
application of clobetasol propionate with ingenol mebutate to reduce local skin reactions 
without impacting efficacy has not yet been investigated.  We are proposing a superiority 
trial for safety as well as a non-inferiority trial for effectiveness.  We will conduct an 
intra-individual, randomized controlled trial at the West Haven Veterans Affairs in 
patients with multiple actinic keratoses, and analyze local skin reactions at day 4 and 
efficacy at day 57.  If combination therapy has significant advantages compared to 







CHAPTER I: INTRODUCTION 
1.1 Background 
Actinic keratoses (AKs) are common precancerous lesions that form in fair-skinned 
individuals with high cumulative ultraviolet (UV) exposure.1-3  In the United States, AKs 
are among the most common reasons for visits to dermatologists.2,4  According to the 
National Ambulatory Medical Care Survey data from 1990 to 1999, AKs were diagnosed 
in more than 47 million visits over these 10 years accounting for 14% of patient visits to 
dermatologists.5  However, this statistic does not reflect the true prevalence of AKs 
because it represent patients who visit dermatologists, suggesting the actual prevalence in 
the general population is much greater than 14%.5,6    
Patients at risk for developing AKs include males with advanced age, fair-skin, high 
cumulative sun exposure, and prolonged immunosuppression.7-10  The most common 
method of AK prevention is sun protection, including avoiding the sun during peak hours 
from 10am to 3pm, wearing protective clothing, and using sunscreen.11  Although there 
has not been a population-based study in the United States to estimate the incidence of 
AKs, it is thought to be increasing as a result of increasing life expectancy, lifestyle 
behaviors such as sun tanning, and increasing cumulative sun exposure.7,8,12  
AKs are a public health concern because if they are not adequately treated they can 
either persist, progress, or develop into invasive squamous cell carcinomas (SCC).13,14  
Although the actual risk of an individual AK progressing to invasive SCC is unclear, 
estimations vary from as low as 0.1% to as high as 20%.13  Lesion directed therapy, such 
as cryotherapy, is commonly used because of its convenience, cost-effectiveness, and 
efficacy.9,15  However, in areas of widespread damage, it is clinically difficult to 
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distinguish which lesions will convert.4,16 Therefore, using field therapy to treat both the 
lesion and the surrounding skin is beneficial because it targets both visible and non-
visible subclinical lesions. 
First-line field therapies include 5- fluorouracil, diclofenac, imiquimod, and 
ingenol mebutate.9,15 Current drawbacks to the self-applied topical field therapies include 
the long duration of treatment and consequently prolonged local reactions, which leads to 
decreased adherence.2  5- fluorouracil has been preferred over other first line therapies 
because of its cost effectiveness and widespread availability, but because it requires 
treatment for four weeks some studies suggest it leads to lower patient satisfaction and 
adherence.9,17  The treatment of choice depends on the patient’s quality of life, 
comorbidities that may contribute to adverse effects, and their ability to adhere to their 
treatment.9  For example, applying topical treatments for an extended duration can be 
especially difficult for the elderly and patients who live alone.15 
Ingenol mebutate (IMB), retrieved from the extract of Euphorbia peplus was 
approved by the FDA in 2012 for the treatment of AK.18,19 The 0.015% IMB gel is 
indicated for a three-day treatment course on the face or scalp, while the 0.05% gel is 
indicated for a two-day treatment course on the trunk or extremities.4  A major advantage 
of IMB therapy over other field therapies is the short treatment time required to yield a 
similar efficacy to 60 days of treatment with diclofenac gel (3.0%) or 16 weeks of 
treatment with imiquimod (5%).20  Studies have shown the adherence to IMB is 98%, 
which can be attributed to the shorter application time.4  However, barriers to treatment 
remain because certain side effects are fairly common in patients using this treatment, 
which can lead to increased cosmetic burden and decreased patient satisfaction.   
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Barriers to effective AK treatment include concerns associated with cosmetic 
effects of treatments, side effects including local skin reactions (LSRs), pain, pruritus, 
cost perceptions, adherence, and long duration time.12  LSR scores are highest on the face 
and scalp compared to the trunk and extremities; this can be attributed to thicker 
epidermis on the scalp and higher absorptive rates compared to other parts of the body.20  
They can be inconvenient for patients and affect their quality of life if LSRs are located 
in areas such as the face or hands.12  
 
1.2 Statement of the Problem 
 
Several studies have shown the efficacy and high adherence rates of IMB, but LSRs, 
one of the most common side effects of IMB, remain a barrier to effective treatment of 
AKs.  LSR scores peak at the 4th day of IMB treatment and usually completely heal in 2 
weeks.20,21  There are several studies that have shown the extent to which LSR reactions  
can lead to reduced quality of life.12  Multiple studies have also shown that when 
compared to another field therapy, IMB has worse LSR, pain, and pruritus scores, giving 
preference to other treatments.22  This can lead to reduced patient satisfaction and 
decreased usage of IMB as a treatment for AKs, especially in the elderly and frail 
population.  
Corticosteroids have been used in many aspects of dermatology, including eczema 
and psoriasis, to reduce inflammation.  Glucocorticoids, such as clobetasol propionate 
have immunosuppressive, anti-inflammatory, and vasoconstrictive properties.  Although 
LSRs are common side effects of field therapies, there is limited research investigating 
the effectiveness of corticosteroids to reduce LSRs.   
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Combination therapy with corticosteroids has shown reduction in inflammation 
caused by cryotherapy and photodynamic therapy.  Research into the effectiveness of 
corticosteroids as combination therapies with IMB to reduce LSR is especially limited.  
Erlendsson et al. is the only randomized controlled trial that has looked at the effect of 
clobetasol propionate after IMB treatment on inflammation and efficacy.23  In their study, 
clobetasol propionate was applied on day 4, when LSR was most severe; no difference 
was found in LSR reduction or in AK clearance. 
Inflammation in IMB is caused by a neutrophil-mediated response, which is required 
to prevent relapse against residual tumor cells.24  The current problem lies in reducing 
this inflammation, without impacting the efficacy of IMB.  Research has shown that 
neutrophil invasion, which is prevented by corticosteroids, is most pronounced in the 
early phase of IMB-induced inflammation, therefore, starting clobetasol propionate on 
day 4 may be too late to impact LSR. Further research is needed to investigate the effect 
of earlier clobetasol propionate treatment on reducing IMB-induced LSR for AK 
treatment.  This study will also add to our understanding about the effect of earlier 
corticosteroid combination therapy on the efficacy of IMB treatment.  
 
1.3 Goals and Objectives 
Our goal is to create a randomized controlled trial that will examine the safety and 
efficacy of earlier corticosteroid application in reducing the severity of LSRs associated 
with IMB therapy.  Our primary objectives are to evaluate the mean reduction of LSR 
scores on day 4 and AK clearance on day 57 in combination therapy with IMB plus 
corticosteroids as compared to IMB alone.  We will evaluate the severity of LSR by using 
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the standardized LSR grading scale created by Rosen et al.25  We will evaluate AK 
clearance clinically and with the use of dermoscopy.  Our secondary objectives are to 
compare the composite pain and pruritus scores of the two groups before and after 





We hypothesize that there will be a statistically significant difference of 2.0 in the 
mean composite LSR score at day 4 in AKs that receive combination therapy with 
ingenol mebutate and clobetasol propionate compared to monotherapy with ingenol 
mebutate alone.  
We also hypothesize that there will be no difference in the visible or dermoscopy 
clearance of AKs treated with combination therapy with ingenol mebutate and clobetasol 
propionate compared to monotherapy with ingenol mebutate alone at day 57.  
 
Definitions 
Safety: mean composite LSR score, pain, and pruritus 
Efficacy: dichotomous outcome that will be evaluated as being greater than 75% visible 
and dermoscopy AK clearance or less than 75% visible and dermoscopy AK clearance at 
day 57.  
Split-face studies: intra-individual studies that compare the application of the control on 
one side of the face to the treatment on the other side of the face.  
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Intra-individual studies: similar to split-face, except they do not divide patients based on 
sides of the face.  Instead one discrete area is chosen as the control and another as the 
treatment and both areas can be on the same side of the face.  
 
Clinical, Dermoscopy, and Visible Characteristics of Actinic Keratosis Grades13 
 Grade I Grade II Grade III 
Clinical Slightly palpable AK, 
which are better felt 
than seen 













with no structure or 
large follicular 
openings filled with 
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CHAPTER II: REVIEW OF THE LITERATURE 
2.1 Introduction 
We conducted a comprehensive medical literature review between November 2016 
and May 2017 to develop this proposed randomized controlled trial.  We searched the 
databases PubMed, Ovid MEDLINE, and Cochrane using the following keywords in a 
variety of combinations: ingenol mebutate, PEP005, 5- fluorouracil, photodynamic 
therapy, cryotherapy, adherence, corticosteroid, clobetasol propionate, actinic keratosis, 
local skin reactions, skin disease, safety, efficacy, and field therapy.  All articles written 
between January 1976 and May 2017 in English were reviewed for significance and 
analyzed. Studies looking at immunocompromised patients or pediatric populations were 
excluded.   
 
2.2 Review of relevant studies 
 
 This section will summarize the existing evidence relevant to the use of IMB in 
the treatment of AKs and focus on measures of safety, which include LSRs, pain, and 
pruritus.  We will also focus on current literature analyzing the long-term efficacy of 
IMB and how this differs from other first-line field therapies.  Data regarding 
combination therapy of IMB and corticosteroids are limited, thus studies analyzing the 
effect of combination therapies with other field treatments for AKs will be reviewed.  We 
will focus on previous research that successfully used corticosteroids to reduce 
inflammation caused by cryotherapy, 5- fluorouracil, and photodynamic therapy without 
compromising efficacy.  Limitations of these studies will also be discussed.     
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2.2.1 Mechanism of Action of Ingenol Mebutate and Corticosteroids   
 Several studies have attempted to analyze how IMB works to clear AKs.  Rosen et 
al. described a dual mechanism of action by IMB, which includes both rapid lesion 
necrosis and neutrophil-mediated, antibody-dependent cellular cytotoxicity.1-3 Mice 
studies showed that rapid lesion necrosis begins 1 to 2 hours after application and is 
followed by a robust inflammatory response.2  Morphologic manifestation of necrotic cell 
death, which was marked by swelling of the mitochondria via an electron microscope, 
was evident as early as 3.5 hours after the addition of IMB in vitro.2  This process likely 
begins with the release of pro-inflammatory cytokines from keratinocytes undergoing 
necrosis, which mediates the neutrophil recruitment.4  The activation and upregulation of 
vascular endothelial adhesion molecules is necessary to allow neutrophils to attach to the 
microvascular endothelium and transmigrate through the vessel wall to reach the 
treatment site.1   
 Challacombe et al. showed infiltration of neutrophils 6 hours after IMB application 
in mice.5  This infiltrative process was clinically apparent on the skin 24 hours later.5  
This neutrophilic reaction is a key component required to prevent relapse against residual 
tumor cells.1,5,6  Neutrophilic activity also results in the inflammation that may cause 
severe LSRs in patients treated with IMB.1,2  More research needs to be conducted on 
combination therapies that can reduce this neutrophil-mediated inflammation without 
compromising the efficacy of IMB.   
There are limited studies investigating the usage of corticosteroids to decrease 
inflammation caused by AK field therapies.  Studies looking at the impact of 
corticosteroids on neutrophils have been mixed.  Systemic and topical corticosteroids are 
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the mainstay of treatments for diseases such Sweets syndrome, which is a neutrophil-
mediated infiltration in the upper dermis.7  However, some studies have shown that 
corticosteroids prolong the life of neutrophils by preventing apoptosis, which would 
theoretically increase inflammation.8    
Corticosteroids are known to have anti-inflammatory, anti-proliferative, 
immunosuppressive, and vasoconstrictive effects.9  Schaefer et al. suggests that the 
mechanism of anti-inflammation is multifactorial; one of these mechanisms is the 
inhibition of the formation of inflammatory proteins released by keratinocytes, 
fibroblasts, and infiltrating leukocytes.10  The anti-inflammatory effects of corticosteroids 
work by inhibiting dermal edema, capillary dilatation, and vascular permeability, which 
prevents the transmission of leukocytes through the vessel wall, and hinders their 
recruitment to the inflammation site.9,11  Glucocorticoids also inhibit cytokine gene 
transcription, T-cell proliferation, and T-cell dependent immunity.11  Generally, topical 
glucocorticoids have both immediate effects that cause membrane stabilization, as well as 
delayed effects that are due to glucocorticoid alteration of DNA transcription.12        
In contrast to Challacombe, Liles et al. suggested that glucocorticoids prolong 
neutrophil survival in vitro by inhibiting apoptosis, which increases the survival of 
circulating neutrophils.8  However, Parrillo et al. hypothesized that circulating 
neutrophils may also increase due to enhanced release from bone marrow cells, or 
because the neutrophils are unable to transmigrate to the site of inflammation.13  
Cronstein et al. showed that pretreatment of endothelial cells with corticosteroids 
prevents them from becoming more adhesive to neutrophils by diminishing stimulated 
expression of ICAM-1 and ELAM-1, which are molecules critical for neutrophil 
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adhesion.14  Earlier use of corticosteroids can prevent the expression of molecules that 
allow neutrophils to adhere to the microvascular endothelium, which may cause a 
decrease in the inflammatory response caused by IMB.14   
Another variant in determining the effectiveness of corticosteroids is their 
potency, which is determined by their anti-inflammatory activity, vasoconstriction 
abilities, and their effect on carbohydrate metabolism.15-17  Clobetasol propionate is a 
Class I, super-potent corticosteroid; in several studies it has been successfully used to 
reduce inflammation caused by AK treatments.18-20  Since the LSRs induced by IMB 
occurs rapidly,15,21-23 we are using a more potent corticosteroid, such as clobetasol 
propionate, that will cause greater vasoconstriction and reduce inflammation quicker than 
a milder corticosteroid.15  Local side effects have been minimal when clobetasol 
propionate has been used for short periods of time (<3 weeks), with transient burning and 
pruritus being the most prominent adverse effects.24   
  In conclusion, the effectiveness of clobetasol propionate relates to its anti-
proliferative, immunosuppressive, vasoconstrictive, and anti-inflammatory effects.  There 
is conflicting evidence on how the mechanism of corticosteroids will affect the 
neutrophil-induced inflammatory response of IMB.  However, most recent research has 
shown that circulating neutrophils may increase after the usage of corticosteroids because 
they cannot transmigrate to the inflammatory loci.  We do not currently understand to 
what extent this will decrease the neutrophil-mediated response, and how this affects the 
efficacy of IMB.  As a result, more studies, such as this one, are needed to investigate the 
role of corticosteroids to reduce IMB-induced LSR without compromising efficacy.  
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2.2.2 Role of Ingenol Mebutate in Actinic Keratosis  
Numerous studies have investigated the safety and efficacy of IMB on the 
treatment of Grades I and II AKs.23,25-27  In a multi-centered, randomized, double-blinded 
study Lebwohl et.al, analyzed 547 patients with face or scalp AKs (277 received IMB 
and 270 placebo) and 458 patients with trunk or extremities AKs (226 received IMB and 
232 placebo) that were treated with IMB 0.015% and 0.05% gel respectively.   
Rate of complete clearance at day 57 was higher in patients treated with IMB on 
the face and scalp as compared to placebo (42.2% vs 3.7%; p<0.001).  Partial clearance 
was also higher in the treatment group (63.9% vs 7.4%; p<0.001).  Efficacy analyses by 
anatomic location of IMB versus placebo demonstrated greater rates of complete 
clearance on the face (47.3% vs 4.1%; p < .001) compared to the scalp (22.8% vs 2.0%; p 
= .001).  Results showed a mean reduction of 83% in the number of AKs treated with 
IMB compared to baseline.    The rate of complete clearance at day 57 was also higher 
with IMB than with placebo for the treatment of trunk and extremities (34.1% vs. 4.7%, 
p<0.001).  Partial clearance was also higher in the treatment group (49.1% vs 6.9%, 
p<0.001), while the mean percentage in reduction in number of AKs from baseline was 
75%.  
Although this study was pivotal in showing the effectiveness of IMB in treatment 
of AKs, there are several limitations of this study. Due to formation of LSRs, participants 
in this study could not be effectively blinded.  Additionally, treatment areas were limited 
to 25 cm2, so the effect of IMB on larger areas was not studied.  The protocol of this 
study prevented adjunctive treatments, so the effect of combination therapy was not 
assessed.  Lastly, because patients diagnosed with AKs have a recurrence rate of 15-53% 
 14 
in the next year,26 it is important to do a follow-up and assess efficacy after day 57, which 
was not performed in this study.  
 Realizing this limitation, Lebwohl et al. used their previously published data and 
analyzed the 3, 6, 9, and 12-month recurrence rate and safety in patients with IMB-
cleared AKs from their previous study.25  The percentage reduction in AKs at 12 months 
from the number of lesions at baseline was 87.2% for the face or scalp and 86.8% for the 
trunk or extremities.  In 53.9% of patients (95% confidence interval [CI]; 44.6 to 63.7) 
one or more lesions developed or recurred in the treatment field.  The sustained clearance 
rate after 12 months of follow-up was 46.1% for patients treated on the face or scalp and 
44.0% for patients treated on the trunk or extremities.    
 To compare this to the efficacy of other first-line field therapies for AKs, 
Krawtchenko et al. studied application of fluorouracil twice daily for 4 weeks (n=24), and 
1 or 2 courses of topical imiquimod 5% administered 3 times per week for 4 weeks each 
(n=26) in AKs.28  Results showed that sustained clearance of treatment at 12 months after 
initial evaluation was 33% for 5-fluorouracil and 73% for imiquimod (p <0.01).  
Although this study is limited by its small sample size, it showed that long term IMB 
efficacy is greater than that of 5-fluorouracil.  
 In order to study improvements in efficacy after reapplication of treatment, Garbe 
et al conduced a randomized, double-blinded study.26  In this study, 450 patients with 4–8 
clinically visible AKs on the face or scalp were treated with 3 days of 0.015% IMB.   
After initial treatment, 61.6% patients showed complete clearance at 8 weeks.  
Remaining patients were randomized to IMB (n = 134) or placebo (n = 69).  For patients 
who received a second treatment cycle, IMB showed significantly higher clearance rate 
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than placebo after 8 weeks (46.7% vs. 18.4%; p < 0.01).  AKs that emerged at week 26 
were also randomized to IMB (n=14) and placebo (n=8) and showed the same success in 
clearance rate (59.5% vs. 25%; p = 0.01).  Overall the complete clearance of AKs 
increased from 61.6% after the initial 3-day treatment to a total of 79.5% by combining 
patients who were completely cleared initially and those who received follow-up 
treatment at 8 weeks.   This study was helpful in proving the long-term efficacy of IMB 
and showed the benefit in repeating treatment for lesions not initially cleared.  
Limitations of the study included the difficulty in blinding patients owing to the lack of 
LSRs in the intervention group during the repeat treatment.  
 Lastly, Siller et al. studied the effect of different IMB concentrations on efficacy at 
day 85 and LSRs on day of treatment.3  In a randomized, double-blinded, multi-centered 
trial, five preselected lesions were treated with IMB gel 0.0025% (n=15), 0.01% (n=16), 
0.05% (n=15), or vehicle gel (n=12), on days 1 and 2 (Arm A) or days 1 and 8 (Arm B).   
Results showed that there was a statistically significant difference in complete clinical 
clearance of 71% of treated lesions in patients that used 0.05% IMB gel compared to 
vehicle gel (P < 0.0001).  The study also showed 80% or greater complete clinical lesion 
clearance in 0.05% IMB gel compared to vehicle (P = 0.0185).  There was not a dose 
response seen histologically, however, this could be due to the small sample size.  
Limitations of the study include its inter-patient variability, which were avoided in other 
studies that used an intra-individual design and larger sample size.  Although the baseline 
characteristics in the control and treatment groups were matched, the vehicle group had 
more females compared to the treatment group (25% vs 7%) and it is unclear if this had 
any effect on the results. 
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2.2.3 Safety of Ingenol Mebutate treatment  
Several studies have analyzed the safety profile of IMB as measured via LSR, pain, 
and pruritus.  Recent post-marketing reports by the U.S. Food and Drug Administration 
have reported severe allergic reactions, herpes zoster, and eye injuries after IMB 
treatment.29  Results of safety in IMB have been mixed, proving the irregularity in 
predicting which patients are more prone to experiencing IMB-induced side effects.  
A meta-analysis conducted by Tzogani et al. looked at 13 IMB clinical trials that 
included 1165 patients.30  The analysis found that most LSRs reported were transient, 
peaked early in the treatment, and resolved within 2 weeks.  However, severe LSRs 
occurred with an incidence of 29% on the face and scalp and 17% on the trunk and 
extremities. 
In addition to measuring efficacy, Lebwohl et al. also looked at safety via LSR 
scores.23  The study noted a peak in the mean maximum composite LSR scores on the 
face and scalp of 9.1±4.1 as compared to 1.8±1.6 in the placebo group.  LSRs generally 
peaked on day 4 and declined afterwards. In the face or scalp studies, 24% of patients 
experienced severe erythema, 9% experienced severe flaking/scaling, and 6% 
experienced severe crusting.  In the trunk and extremities LSRs were less common 
(6.8±3.5 vs 1.6±1.5) and peaked on days 3, 8, and 15. The study found the most common 
adverse effect reported was pain (13.9%) and pruritus (8%).   
Goldenberg et al. conducted a randomized, double-blinded, vehicle-controlled trial to 
evaluate the safety, tolerability, and efficacy of 0.015% IMB applied 3 weeks after 
cryotherapy to AKs on the face and scalp.31  The mean (95% CI) composite LSR score at 
day 3 in patients treated on the face (n=120) was higher 9.3 (95% CI; 8.5–10.1) compared 
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to the scalp (n=36) 5.8 (95% CI; 4.3–7.4).  This may be due to thinner skin and fewer hair 
follicles on the face compared to the scalp.31  Scalp AKs can be thicker, and therefore 
absorb IMB less efficiently than the face.31  This study showed that face LSR severity in 
patients receiving combination therapy with cryotherapy and IMB was similar to LSR 
scores seen with IMB alone in Lebwohl et al.23     
Bettencourt et al. conducted a retrospective chart review from a community 
dermatology practice to study 78 males treated with 0.05% IMB on the scalp.32  Usually, 
for the scalp, 0.015% IMB is recommended.  However, the author noted that in his own 
practice, 41% of patients who received 0.015% formulation had persistent AKs, so he 
used 0.05% instead.  Additionally, 83% of the patients reviewed had received 
cryosurgery 2 weeks before IMB treatment for the scalp AKs.  The study noted all 
patients experienced erythema (n=78, 100%), and a majority had flaking/scaling (n=76, 
97%) and crusting (n=48, 66%).  Most patients experienced mild to moderate reactions 
that resolved in 2 weeks, except one patient whose reaction did not resolve until day 20.  
This study shows that IMB-induced LSR affects a majority of patients 
A limitation of this study is that AK clearance in patients was not compared to those 
treated with cryosurgery alone or with 0.05% IMB gel alone. Since most patients had 
undergone cryotherapy 2 weeks prior to IMB, it is difficult to determine how much LSR 
was caused by IMB versus residual inflammation from cryotherapy.  Therefore, the 
author cannot know to what extent the 0.05% IMB formulation contributed to AK 
clearance or LSRs.  Also this was a retrospective study conducted from a single 
dermatology clinic, which provides a very limited sample size.  This study only looked at 
males, so we also do not understand the effects this would have on a female population.   
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Both IMB and methyl-aminolevulinate photodynamic therapy (MAL-PDT) are 
preferred field therapies because of their short duration times.  MAL-PDT needs only one 
therapeutic session, with a second session required only if there is partial removal.  
However, both field therapies have significant side effects including erythema and pain.   
Genovese et al. conducted an intra-individual study that compared the effectiveness, 
tolerability, and patient preference of daylight-photodynamic therapy with methyl-
aminolevulinate (D-PDT-MAL) vs IMB in patients with grade I and II AKs on the face 
and scalp.33  This study analyzed 27 patients with a total of 323 AKs, of which 215 were 
grade I and 108 were grade II. The mean number of AKs in a treatment group were 
similar (D-PDT-MAL 6.2 ± 63.4 vs IMB 5.7 ± 63.6; p=0.4).  Mean AK clearance rate at 
3 months was found to be similar between the two groups (D-PDT-MAL 72.4% vs IMB 
73.6%; p=0.74).  D-PDT-MAL was associated with lower LSR scores at week 1 and 
month 1 as compared to IMB. At week 1 average LSR score was 2± 1.1 (range 0–4), for 
D-PDT-MAL areas and 8.9± 3.8 (range 2–15) for IMB areas (LSR= 6.9; p<0.0001). At 
1 month, mean LSR score was 0.5± 0.7 (range 0–3) for D-PDT-MAL areas and 3.2± 1.9 
(range 0–6) for IMB areas (LSR= 2.7; p<0.0001).  Average patient Visual Analog Scale 
(VAS) satisfaction score was greater for D-PDT-MAL compared to IMB (8 ± 2.1 vs 7.5 
±2.1; p=0.15).  Although the results were not statistically significant, 14 (56%) of 
patients preferred D-PDT-MAL compared to 3 (12%) that preferred IMB.  This study 
also noted that clearance rate of grade I and grade II AKs treated with IMB was similar at 
3 months (76.7% vs. 72.8%; p=0.28).  
In a similar randomized, split-faced study, Moggio et al. evaluated treatment 
outcomes, such as erythema, pain, and clearance for D-PDT-MAL vs IMB.34   In this 
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study, a total of 22 patients with 311 AKs were enrolled at the University of Brescia, 
Northern Italy.  The mean pain VAS score was higher in IMB compared to D-PDT-MAL 
(3.55 ± 1.82 vs 2.05 ± 0.72; p < 0.01). The mean LSR score was also higher in IMB (9.91 
± 4.24 vs 4.59 ± 4.03; p < 0.01).  However, AK clearance at 3 months was found to be 
similar between IMB and D-PDT-MAL (75.8% vs 77.9%; 95% CI from −0.21 to 0.11).  
Similarly, Zane et al. conducted a single-center, prospective, open-label, split-face, 
clinical trial to compare efficacy, LSR, and patient preference of MAL-PDT versus 
0.015% IMB on the treatment of face and scalp AKs.  Using 35 patients, complete 
clearance of AKs was similar between IMB and MAL-PDT at 3 months (62.9% vs 
67.1%; p= non-significant).  Pain score was determined using the VAS, which showed 
that IMB was less painful than MAL-PDT (3.74 ± 2.28 vs 5.46 ± 3.05; p < 0.01), which 
differs from Moggio et al.  However, LSR was still found to be more severe with IMB 
compared to MAL-PDT (11.17 ± 5.29 vs 6.69 ± 2.88; p < 0.01).  In a survey eliciting 
patient preference, it showed patients preferred MAL-PDT (60% vs 40%).  Both these 
studies demonstrated that the efficacy between MAL-PDT and IMB was not statistically 
different, but patients preferred MAL-PDT over IMB, which could be due to better 
cosmetic outcome.  This can have a strong impact on the adherence of patients, especially 
if they are elderly or frail, and can influence the effectiveness of the treatment in real 
life.35 
Reviewing studies of IMB-induced LSR shows a wide variability in patients. This is 
parallel to what Longo et al., reported in a case series (n=4) of patients treated with IMB 
with maximum LSR scores on the face and scalp ranging from 11 to 23.36  Although 
studies state that patients experience mostly mild to moderate LSRs during AK treatment 
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with IMB, there is an unpredictability in knowing who will experience severe reactions.  
We have also seen that higher concentrations of IMB are more efficacious, but are 
generally less tolerated as they induce more LSRs.       
2.2.4 Relationship Between Inflammation and Efficacy of IMB 
Jim et al. conducted a regression analysis to determine if the extent of AK clearance 
was determined by the intensity of the inflammatory LSRs.  They collected data from 2 
double-blinded, randomized studies (n=218) that evaluated IMB 0.015% for treating AKs 
of the face and scalp.  The analysis looked at week 8 AK count, compared to baseline, 
along with day 4 LSR to create a 90% prediction for percent reduction in AK count.  
Results showed the mean reduction from baseline in AK count was 78% (95% CI; 73%- 
81%) and the mean day 4 composite LSR score was 9.2 (95% CI; 8.7- 9.8).  The 
regression predicted that a composite LSR score of 15 will create an expected percentage 
reduction in AKs of 88.1%, LSR score of 10 an expected reduction of 80.7%, and LSR 
score 5 an expected reduction of 68.6%. 
This study is the only study designed to analyze a possible relationship between 
composite LSR score and treatment efficacy.  However, it has only looked at 2 
randomized controlled trials to conduct its regression analysis.  The effect of 
corticosteroid on IMB is not well understood.  The mechanism of action of corticosteroid 
is multi-factorial, thus, we cannot accurately predict how it will interact with the 
neutrophil-mediated inflammatory response.  It is unclear if this possible interaction will 
decrease LSR scores and thus decrease efficacy, or, as seen in previous studies, it will 




Figure 1.  Expected percentage reduction from baseline for face-treated AKs based on 
regression analysis of AK counts at day 57 and composite LSR Score on day 4. 
2.2.5 Role of Combination Therapy with Corticosteroid 
A limited number of studies have investigated the role of combination therapy 
with corticosteroids to reduce AK treatment-induced LSR.   In the past 40 years, a 
handful of studies have conducted randomized controlled trials to examine the effect of 
corticosteroids on first-line AK field therapies, such as fluorouracil, cryotherapy, PDT, 
and IMB.   
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In dermatology practice, the application of topical corticosteroids 15 minutes after 
5-fluorouracil cream has been shown to be helpful in reducing the inflammatory 
response.37  Breza et al. was the first study to examine the impact of triamcinolone on 
fluorouracil-induced inflammation.38  In a randomized, intra-individual, trial at the 
Veterans Administration Hospital in Miami, patients with moderate to severe AKs (n=19) 
were treated on both sides of the face with 1% fluorouracil in propylene glycol.  This 
acted as the control, while one side of the face was chosen as the experimental side, in 
which three different interventions were used.  Group 1 (n=5) had treatment with 0.4% 
triamcinolone acetonide dissolved into the 1% fluorouracil solution of propylene glycol.  
Group 2 (n=5) had 0.5% triamcinolone acetonide cream applied 10 to 15 minutes after 
the solution dried and Group 3 (n=5) had 0.1% triamcinolone acetonide cream likewise 
applied 10 to 15 minutes after the solution dried.  During the initial four weeks of the 
study, two physicians judged the degree of redness, pruritus, dryness, irritation, 
inflammation, and crusting on each side of the face, and determined that Group 1 and 2 
had noticeably suppressed inflammation.  Findings were reported as none, left side 
greater than right, right side greater than left, or equal on both sides.  The physicians were 
not blinded, the sample size was limited, and there was not an independent, quantitative 
grading scale used to assess the reduction of inflammation. However, this was the first 
study that attempted to study the impact of corticosteroids on reducing LSRs induced by 
AK therapies. It also showed that triamcinolone of higher potency may be more effective 
in treating inflammation without affecting the efficacy of treatment.  
Two studies examined the efficacy of clobetasol propionate to reduce 
inflammation caused after cryotherapy.  In a double blinded, randomized, placebo-
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controlled trial, Hindson et al. studied 19 patients with basal cell carcinoma (BCC) and 
18 patients with viral warts of the hands.18  Patients were randomly assigned to 
application of clobetasol propionate or an ointment base immediately after cryotherapy. 
The degree of inflammation was estimated by measuring the volume of the lesions before 
and after cryotherapy via a mold formed by alginate dental cement.  Results showed that 
24 hours after cryosurgery there was a reduction in the percentage volume increase for 
clobetasol propionate versus ointment group in BCC patients (44.81± 21.95 vs 145.83 ± 
44.72; p<0.001).  Similar results were seen in patients with viral warts (53.50 ± 50.20 vs 
183.0 ± 126.0; p<0.02). 
There are several limitations to this study.  Firstly, there is no evidence showing 
that alginate dental cement volume measurements are an accurate way of determining 
inflammation.  Secondly, patients with BCCs got a local injection of 0.1% lignocaine 
prior to cryotherapy and it is unclear what impact, if any, receiving anesthetic caused on 
reducing inflammation.  The average size of the lesions prior to treatment was not 
revealed in the study, so it is unclear if smaller lesions were chosen predominantly for the 
clobetasol propionate group while the ointment base received larger lesions that may 
cause more erythema after cryotherapy. Although this study was conducted on patients 
with BCC and warts, it is the first study to examine the benefit of corticosteroids on 
reducing inflammation caused by cryotherapy. 
To investigate the impact of clobetasol propionate on cryotherapy-induced 
erythema on normal skin, Humphreys et al. developed a smaller, single-blinded, intra-
individual, randomized controlled trial, using 10 patients.19  These patients applied 
cryotherapy on both arms, but applied 0.05% clobetasol propionate only on one.  Both 
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arms were occluded with dressing for 4 hours to increase the penetration of the treatment.  
Independent evaluators measured erythema at 24 and 48 hours using a reflectance 
instrument that obtains an erythema index, measured via the blood content of the dermis.  
Results showed a significant reduction in the mean change in erythema among patients 
that applied 0.05% clobetasol propionate after cryotherapy compared to those with 
cryotherapy alone at 24 hours (40 ± 10 versus 85 ± 20; P<0.05) and 48 hours (82 ± 16 
versus 137 ± 20; P<0.05).  This trial was conducted with a small sample size and as a 
result it is difficult to evaluate the external validity of this study.  Additionally, the 
reliability of the erythema index used to evaluate inflammation is unknown.  
More recently, Wiegell et al. conducted a randomized controlled trial to evaluate 
the effect of clobetasol propionate treatment just before and after PDT treatment for AKs 
to reduce inflammation without compromising efficacy.20  Post-treatment erythema is a 
major side effect of PDT and this prevents its usage in large areas.39  This intra-individual 
study looked at 22 patients with AKs in the face and scalp and randomized them to 
combination therapy with clobetasol propionate 15 minutes before and after treatment, or 
to monotherapy with PDT alone.   
Erythema was measured subjectively using a visual 4-point scale by blinded 
investigators the day after PDT treatment.  It was also measured objectively using a skin-
reflectance meter that measures skin remittance at 558 nm and 660 nm and calculates the 
content of melanin and hemoglobin in the skin.  Erythema was scored on a scale from 0 
to 100 and the mean value from measurements at five different sites was used for 
statistical analysis. Erythema was measured three times: before the application of topical 
steroid and lesion preparation, just after red LED illumination, and the day after PDT 
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treatment. The primary outcome measure of the study was increased erythema measured 
by the skin-reflectance meter, 1 day after treatment compared with baseline. 
Results showed that clobetasol propionate significantly reduced erythema 24 
hours after treatment in the corticosteroid-receiving PDT lesions compared to PDT alone 
(48.4 vs 52.8; p =0.007).  The total erythema increase from baseline was only 7 points in 
the combination group versus 16 points in the monotherapy group (P=0.012).  At a 3-
month follow-up a total of 22 new AK lesions had developed in the monotherapy group 
versus 21 in the combination therapy (P = 0.58), suggesting that steroid treatment did not 
affect efficacy. 
Erlendsson et al. is the only randomized controlled trial that has looked at the effect 
of clobetasol propionate after IMB treatment.21  In a blinded, intra-individual, 
randomized controlled clinical trial looking at 21 patients with Grades I to III AKs on the 
face or scalp, two areas were treated with 0.015% IMB daily for three days.  One area 
was randomized to receive topical 0.05% clobetasol propionate twice daily for 4 days.  
Assessments included LSR (0-24; days 1, 4, 8, 15, 57), pain (0-10) and pruritus (0-3; 
days 1-15), AK clearance (days 15, 57), and cosmetic outcome (0-3; day 57).   
Control and treatment groups had similar LSR scores at day 4, prior to clobetasol 
propionate initiation (IMB 9.95 vs IMB+ clobetasol propionate 9.52; P = 0.285).  
Clobetasol propionate application was performed from days 4-7; day 8 results showed 
LSR between the two groups was not significant (IMB 6.81 vs IMB+ clobetasol 
propionate 6.81; P = 0.939).  LSRs returned to baseline in both groups (IMB 0.67 vs 
IMB+ clobetasol propionate 0.38; p=0.250) by week 2.  Pain was mild to moderate in 
patients and peaked at day 3 (IMB 2.6 vs IMB+ clobetasol propionate 2.9; p = 0.500) and 
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declined gradually thereafter. Pruritus peaked on day 7 (IMB 1.0 vs IMB+ clobetasol 
propionate 1.2; p = 0.312).  There was no difference found in pain between the two 
groups. However, pruritus on day 9 was greater in the combination group (0.8 vs 1.1; 
p=0.042).  AK clearance between monotherapy and combination therapy at week 8 was 
similar (86% vs 86%; p =0.991). 
IMB is generally used in AKs grade I and II, but this study also looked at the efficacy 
of IMB in Grade III hyperkeratotic AKs.  Results of all AK grades were combined and 
presented together so it is unclear how IMB-induced LSR differed in patients with Grade 
III AKs.40  The study demonstrated that although the application of a glucocorticoid after 
finalized IMB treatment does not alleviate IMB-induced LSR, pain, or pruritus, the 
treatment does exert a therapeutic effect on all AK severity grades. 
A limitation of Erlendsson et al. includes their short follow-up time as they did not 
analyze the efficacy and safety of the treatment after 2 months.  Additionally, the study 
was designed to have enough power to detect a relative reduction in LSR scores, but was 
not powered to assess efficacy between outcomes. 
2.2.6 Reviews of Studies Analyzing Possible Confounding Variables  
 Since this is an intra-individual study there are limited confounding variables.  
Baseline demographics of the patients will be analyzed for age, gender, race, ethnicity, 
geographic location, Fitzpatrick skin type, history of prior skin cancer, or previous AK 
treatments..23  Lebwohl et al. found that majority of patients with widespread AK damage 
were Fitzpatrick I or II, approximately half had a history of skin cancer, and more than 
75% had received prior cryotherapy.23  AK characteristics such as mean AK lesion count 
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and location of lesions on the face will also be evaluated.31  The size and location of the 
AKs can potentially impact the degree of irritation caused by IMB and thus the ability of 
the corticosteroid to influence this irritation.34  If the severity of LSRs is related to 
selective absorption by abnormal skin, the degree of absorption into the abnormal AKs 
may be another differentiating factor.31  
 
2.3 Review of relevant methodology 
2.3.1 Study Design and Setting 
Multiple studies have assessed the efficacy and safety of ingenol mebutate using 
an intra-individual randomized controlled trial.21,33,38,41  This has several advantages 
because it reduces confounding and inter-patient variability.3  Our study will focus on 
participants chosen from the West Haven VA as this includes a representative population 
of patients that generally develop AKs.38,42  As seen in Erlendsson et al. and Moggio et 
al. randomization of lesions receiving clobetasol propionate will be done via 
consecutively numbered, closed, nontransparent envelopes containing a computer-
generated allocation.21,34  Based on our hypothesis that patients without corticosteroids 
will experience greater LSRs, it will likely be difficult to blind patients, so we will 
conduct a single-blinded study.23,26    
2.3.2 Selection Criteria 
Inclusion criteria will include patients with the presence of four to eight clinically 
typical, visible, and discrete AKs within a 25 cm2 contiguous field on the face.21,23,31  
Goldenberg et al. showed that LSRs are less severe on the scalp versus the face.31 
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Lebwohl et al. demonstrated the complete clearance was greater on the face (47.3% vs 
4.1%; P < .001) compared to the scalp (22.8% vs 2.0%; P = .001).23   Thus, to reduce 
confounding, our proposed study will only evaluate patients with AKs on the face.   
The median age of patients in randomized controlled trials looking at IMB is 
generally between 60-75, because elderly patients are more likely to get AKs.20,31  
Prevalence in the southern hemisphere is thought to be 60% in individuals over the age of 
40 years.30  Thus, our selection criteria will include patients above the age of 40, which 
would effectively represent 80% of the veteran population living in Connecticut.42  There 
are no well-controlled studies of IMB gel in pregnant patients, therefore female subjects 
must be of either non-childbearing potential, post-menopausal, or use some form of 
contraception.34  All patients must have the ability to follow trial instructions and written 
informed consent must be obtained prior to any trial-related procedures.  Agreement from 
the subjects must allow photographs of the selected treatment area to be taken and used 
as part of the study data package. 
IMB gel has not been well studied in certain populations so patients will not be 
enrolled if they had a recent transplantation, are immunosuppressed, have other severe 
systemic infections, or Olsen’s grade III AK.34,43  Patients with known allergies to any 
molecule in IMB or corticosteroids will also be excluded.44,45  As seen in Moggio et al. 
patients will be excluded if they have had any prior field therapy, including IMB, for 
their AKs within a period of 6 months.3,34  Areas within 5 cm of an incompletely healed 
wound or within 10 cm of a suspected BCC or SCC will not be included in the study.23  
Additionally, as seen in Erlendsson et al. and Lebwohl et al., we will exclude patients 
who recently used medications or treatments that could interfere with study results (e.g., 
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topical medications, artificial tanners, immunomodulating agents, cytotoxic drugs, UVB 
phototherapy, corticosteroids, or an oral retinoid).21,23    
2.3.3 Intervention and Method of Administration 
The safety in IMB is most commonly evaluated by LSR.1,4,31,34  Of note, the FDA 
has recently reported several cases of severe allergic reactions and herpes zoster 
associated with the use of IMB.29  There are also reports of severe eye injuries that have 
occurred with incorrect IMB usage, involving patients accidentally transferring IMB 
from the hands to eyes or lips via cosmetic application or insertion of contact lenses.29  
No clinical IMB trial has reported these adverse effects in patients.  Although our study 
will not focus on these side effects, we will include detailed information regarding these 
safety issues on our patient consents so participants are aware and know how to avoid 
them.  Instructions on home application of treatment and importance of proper hand wash 
will be presented both on paper and verbally.  Researchers and patients will apply a one 
unit-dose tube of 0.015% IMB gel to cover the chosen 25cm2 areas and let it dry for 15 
minutes before applying corticosteroids.   
Topical corticosteroids can cause local side effects such as epidermal thinning, 
dermal striae, atrophy, telangiectasia, purpura, and tachyphylaxis.15  Systemic side effects 
such as suppression of HPA axis, growth stunting in children, and Cushing's syndrome 
have been reported, but are rare.  The systemic effects of topical corticosteroids depend 
on how they are absorbed through the skin and the pharmacokinetics and potency of the 
corticosteroid chosen.44  Absorption can increase depending on factors such as steroid 
occlusion, application site, skin integrity, and application frequency.12  Adverse effects 
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increase when potent steroids are applied over large areas.  This study will attempt to 
reduce these effects by applying a thin layer of clobetasol propionate 0.05% ointment, 
without occlusion, to a small (25cm2) treatment allocated area once a day21,22 for a 
maximum duration of 8 days, thus limiting overall systemic absorption and side effects.   
2.3.4 Outcome 
Primary Outcome: Local Skin Reaction at day 4 and AK clearance at day 57 
Rosen et al. developed an objective and quantitative scale that includes six typical 
LSRs: erythema, flaking/scaling, crusting, swelling (edema), vesiculation/pustulation, 
and erosion/ ulceration.  They are measured from a scale of 0-4, for a cumulative sum of 
24.  There are accompanying photographs that correlate the severity of LSR to the 
numerical scale.  This scale has been verified by the Australian College of 
Dermatologists, shows good inter-observer grading concordance, and has been used in 




Figure 2. The LSR grading scale is a quantitative scale for the evaluation of LSRs 
arising from topical ingenol mebutate treatment. 
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Jim et al., showed that the absolute reduction in LSR scores was dependent on the 
day 4 composite score.40  A total of 220 patients were treated for AKs on the face, and 56 
patients were treated for AKs on the scalp.  A simple regression model showed that the 
composite LSR score on day 4 can be used to predict the week 1, 2, 4, and 8 composite 
LSR scores and is a significant predictor in the resolution of LSRs.  The importance of 
assessing the LSR severity on the 4th day has also been established in other studies.23,26,27  
Thus, our study will also use the mean LSR composite score on day 4 as the main data 
point to evaluate safety in the two groups and predict overall outcomes.      
Several studies have established the 57th day of treatment as an endpoint for AK 
clearance.21,23,46  Our study will emulate these data and measure a reduction of 75% or 
more in the number of clinically visible and dermoscopy AKs in the target treatment area 
at week 8.  
 
Secondary Outcome: Pain, pruritus, and AK clearance at 1 year 
Our secondary outcomes will measure differences in pain and pruritus scores as 
these are the most common side effects reported after the usage of IMB.21,27  There are 
limited studies specifically stating days when application site pain and pruritus were 
analyzed, so we will follow Erlendsson et al. and measure pain (0-10) and pruritus (0-3) 
using a VAS from days 0-15.  Patients will record pain and pruritus using a VAS log at 
home and they will also be asked about this during office visits.21  In order to establish 





Our study will use a patient adherence survey and verbal questioning to assess 
medication compliance.  Studies have consistently shown that patient-reported adherence 
is higher than objective measures of adherence.47  Measurements using Medication Event 
Monitoring System cap to measure overall adherence can be used as a more objective 
measure of adherence. However, this tool will not tell us how the medication was used, 
when it was applied, to what it was applied, and how much was applied to each area.48  
 
Sample Size and Statistical Significance 
Many intra-individual studies have calculated the sample size using a significance 
level of 0.05 and a power of 80%.20,21,33,34  We have two primary hypotheses to assess 
improvement in safety and non-inferiority in efficacy between combination therapy and 
monotherapy.  It is not reasonable to calculate our sample size based on a superiority test 
since testing a non-inferiority hypothesis will require a larger sample size.49  Thus, we 
will be using a two-sided one-sample t-test to calculate our sample size.  Erlendsson et al. 
reported the LSR for IMB group was 9.95 before application of clobetasol propionate.21 
We will calculate our sample size based on a standard deviation of 4 and a 2.0 difference 
in relative reduction, which corresponds to 20% reduction after treatment.21  Using the 
Power Analysis and Sample Size software and a two-sided one-sample t-test with 
alpha=0.05, we calculated a sample size of 34 (Appendix A).  
Our second hypothesis is testing non-inferiority in efficacy between the treatment and 
control group.  Garbe et al. established a 15% -55% difference as significant for AK 
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clearance, and Moggio et al. established a non-inferiority margin of 20%.26,34  Since no 
study looking at corticosteroid combination therapies has established a non-inferiority 
margin, we will extrapolate data from these two studies.  We used McNemar’s test to 
determine a sample size of 34 patients will have 80% power to detect difference in paired 
proportions of 26% - 34% between two arms.  We will use this sample size to evaluate 
our primary outcome of AK clearance.  To ensure adequate sample size, we will account 
for a 5% lost to follow-up, which brings our sample size up to 36.21    
2.4 Conclusion 
In conclusion, multiple studies have hypothesized that the inflammatory response 
generated by IMB is caused by neutrophilic infiltration.36  There are various theories on 
the role of corticosteroids on neutrophils, however several studies have shown that it 
works to reduce inflammation by preventing the transmigration of neutrophils to the 
inflammatory loci.5,13  Although several studies have analyzed the impact that 
corticosteroids have in reducing erythema associated with AK field therapies, only one 
study has previously looked at the impact of combining glucocorticoids with IMB to 
study its efficacy and safety.  This will be the first study done in the United States to 
study the application of clobetasol propionate before, during, and after IMB treatment 
and analyze the impact on LSR reduction and long term efficacy. By conducting this 
study, we will understand whether the immunosuppressive properties of corticosteroids 
will counteract the immune-stimulating effects of IMB and render it ineffective, or if the 




1. Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate 
gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by 
lesion-specific immune response. J Am Acad Dermatol. 2012;66(3):486-493. 
2. Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl 
angelate: plasma membrane and mitochondrial disruption and necrotic cell death. 
Cancer Res. 2004;64(8):2833-2839. 
3. Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol 
mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a 
randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. 
Australas J Dermatol. 2009;50(1):16-22. 
4. Rosen R, Marmur E, Anderson L, Welburn P, Katsamas J. A new, objective, 
quantitative scale for measuring local skin responses following topical actinic 
keratosis therapy with ingenol mebutate. Dermatol Ther (Heidelb). 
2014;4(2):207-219. 
5. Challacombe JM, Suhrbier A, Parsons PG, et al. Neutrophils are a key component 
of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J 
Immunol. 2006;177(11):8123-8132. 
6. Martin G, Swanson N. Clinical findings using ingenol mebutate gel to treat actinic 
keratoses. J Am Acad Dermatol. 2013;68(1 Suppl 1):S39-48. 
7. Cohen PR. Sweet's syndrome--a comprehensive review of an acute febrile 
neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2:34. 
8. Liles WC, Dale DC, Klebanoff SJ. Glucocorticoids inhibit apoptosis of human 
neutrophils. Blood. 1995;86(8):3181-3188. 
9. Norris DA. Mechanisms of action of topical therapies and the rationale for 
combination therapy. J Am Acad Dermatol. 2005;53(1 Suppl 1):S17-25. 
10. Schafer-Korting M, Kleuser B, Ahmed M, Holtje HD, Korting HC. 
Glucocorticoids for human skin: new aspects of the mechanism of action. Skin 
Pharmacol Physiol. 2005;18(3):103-114. 
11. Hughes J, Rustin M. Corticosteroids. Clin Dermatol. 1997;15(5):715-721. 
12. Abidi A, Ahmad F, Singh SK, Kumar A. Study of reservoir effect of clobetasol 
propionate cream in an experimental animal model using histamine-induced 
wheal suppression test. Indian J Dermatol. 2010;55(4):329-333. 
13. Parrillo JE, Fauci AS. Mechanisms of glucocorticoid action on immune processes. 
Annu Rev Pharmacol Toxicol. 1979;19:179-201. 
14. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism 
for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor 
regulates leukocyte adhesion to endothelial cells and expression of endothelial-
leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl 
Acad Sci U S A. 1992;89(21):9991-9995. 
15. Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician. 
2009;79(2):135-140. 
 36 
16. Parente L. Deflazacort: therapeutic index, relative potency and equivalent doses 
versus other corticosteroids. BMC Pharmacol Toxicol. 2017;18(1):1. 
17. Mehta AB, Nadkarni NJ, Patil SP, Godse KV, Gautam M, Agarwal S. Topical 
corticosteroids in dermatology. Indian J Dermatol Venereol Leprol. 
2016;82(4):371-378. 
18. Hindson TC, Spiro J, Scott LV. Clobetasol propionate ointment reduces 
inflammation after cryotherapy. Br J Dermatol. 1985;112(5):599-602. 
19. Humphreys F, Spiro J. The effects of topical indomethacin and clobetasol 
propionate on post-cryotherapy inflammation. Br J Dermatol. 1995;132(5):762-
765. 
20. Wiegell SR, Petersen B, Wulf HC. Topical corticosteroid reduces inflammation 
without compromising the efficacy of photodynamic therapy for actinic keratoses: 
a randomized clinical trial. Br J Dermatol. 2014;171(6):1487-1492. 
21. Erlendsson AM, Karmisholt KE, Haak CS, Stender IM, Haedersdal M. Topical 
corticosteroid has no influence on inflammation or efficacy after ingenol mebutate 
treatment of grade I to III actinic keratoses (AK): A randomized clinical trial. J 
Am Acad Dermatol. 2016;74(4):709-715. 
22. Jim On S, Knudsen KM, Skov T, Lebwohl M. Regression Analysis of Local Skin 
Reactions to Predict Clearance of Actinic Keratosis on the Face in Patients 
Treated With Ingenol Mebutate Gel: Experience from Randomized Controlled 
Trials. J Drugs Dermatol. 2017;16(2):112-114. 
23. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol 
mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010-1019. 
24. Olsen EA, Cornell RC. Topical clobetasol-17-propionate: review of its clinical 
efficacy and safety. J Am Acad Dermatol. 1986;15(2 Pt 1):246-255. 
25. Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK. Long-
term follow-up study of ingenol mebutate gel for the treatment of actinic 
keratoses. JAMA Dermatol. 2013;149(6):666-670. 
26. Garbe C, Basset-Seguin N, Poulin Y, et al. Efficacy and safety of follow-up field 
treatment of actinic keratosis with ingenol mebutate 0.015% gel: a randomized, 
controlled 12-month study. Br J Dermatol. 2016;174(3):505-513. 
27. Berman B. Safety and tolerability of ingenol mebutate in the treatment of actinic 
keratosis. Expert Opin Drug Saf. 2015;14(12):1969-1978. 
28. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A 
randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. 
cryosurgery in immunocompetent patients with actinic keratoses: a comparison of 
clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 
2007;157 Suppl 2:34-40. 
29. FDA Drug Safety Communication: FDA warns of severe adverse events with 
application of Picato (ingenol mebutate) gel for skin condition; requires label 
changes. 2015; https://www.fda.gov/Drugs/DrugSafety/ucm459142.htm, 2017. 
30. Tzogani K, Nagercoil N, Hemmings RJ, et al. The European Medicines Agency 
approval of ingenol mebutate (Picato) for the cutaneous treatment of non-
hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the 
 37 
scientific assessment of the Committee for Medicinal Products for Human Use 
(CHMP). Eur J Dermatol. 2014;24(4):457-463. 
31. Goldenberg G, Berman B. Assessment of local skin reactions with a sequential 
regimen of cryosurgery followed by ingenol mebutate gel, 0.015%, in patients 
with actinic keratosis. Clin Cosmet Investig Dermatol. 2015;8:1-8. 
32. Bettencourt MS. Tolerability of Ingenol Mebutate Gel, 0.05%, for Treating 
Patients with Actinic Keratosis on the Scalp in a Community Dermatology 
Practice. J Clin Aesthet Dermatol. 2016;9(3):20-24. 
33. Genovese G, Fai D, Fai C, Mavilia L, Mercuri SR. Daylight methyl-
aminolevulinate photodynamic therapy versus ingenol mebutate for the treatment 
of actinic keratoses: an intraindividual comparative analysis. Dermatol Ther. 
2016;29(3):191-196. 
34. Moggio E, Arisi M, Zane C, Calzavara-Pinton I, Calzavara-Pinton P. A 
randomized split-face clinical trial analyzing daylight photodynamic therapy with 
methyl aminolaevulinate vs ingenol mebutate gel for the treatment of multiple 
actinic keratoses of the face and the scalp. Photodiagnosis Photodyn Ther. 
2016;16:161-165. 
35. Zane C, Fabiano A, Arisi M, Calzavara-Pinton P. A Randomized Split-Face 
Clinical Trial of Photodynamic Therapy with Methyl Aminolevulinate versus 
Ingenol Mebutate Gel for the Treatment of Multiple Actinic Keratoses of the Face 
and Scalp. Dermatology. 2016;232(4):472-477. 
36. Longo C, Neri L, Argenziano G, et al. Management of local skin reactions after 
the application of ingenol mebutate gel for the treatment of actinic keratosis: four 
illustrative cases. J Eur Acad Dermatol Venereol. 2016;30(2):320-321. 
37. Dodds A, Chia A, Shumack S. Actinic keratosis: rationale and management. 
Dermatol Ther (Heidelb). 2014;4(1):11-31. 
38. Breza T, Taylor R, Eaglstein WH. Noninflammatory destruction of actinic 
keratoses by fluorouracil. Arch Dermatol. 1976;112(9):1256-1258. 
39. Dreno B, Amici JM, Basset-Seguin N, et al. Management of actinic keratosis: a 
practical report and treatment algorithm from AKTeam expert clinicians. J Eur 
Acad Dermatol Venereol. 2014;28(9):1141-1149. 
40. Jim On SC, Knudsen KM, Skov T, Lebwohl M. Relationship between severity of 
the local skin reactions and the rate of local skin reaction resolution in patients 
treated with ingenol mebutate gel. Clin Cosmet Investig Dermatol. 2016;9:211-
216. 
41. Hashim PW, Nia JK, Singer S, Goldenberg G. An Investigator-initiated Study to 
Assess the Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After 
Cryosurgery in the Treatment of Hypertrophic Actinic Keratosis on Dorsal Hands. 
J Clin Aesthet Dermatol. 2016;9(7):16-22. 
42. National Center for Veterans Analysis and Statistics. 2016; 
https://www.va.gov/vetdata/Veteran_Population.asp, 2017. 
43. Samorano LP, Torezan LA, Sanches JA. Evaluation of the tolerability and safety 
of a 0.015% ingenol mebutate gel compared to 5% 5-fluorouracil cream for the 
treatment of facial actinic keratosis: a prospective randomized trial. J Eur Acad 
Dermatol Venereol. 2015;29(9):1822-1827. 
 38 
44. Chi CC, Kirtschig G, Aberer W, et al. Updated evidence-based (S2e) European 
Dermatology Forum guideline on topical corticosteroids in pregnancy. J Eur Acad 
Dermatol Venereol. 2017;31(5):761-773. 
45. FDA Full Prescribing Information 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202833s004lbl.pd
f. Accessed June 12, 2017, 2017. 
46. Bourcier M, Stein Gold L, Guenther L, Andreassen CM, Selmer J, Goldenberg G. 
A dose-finding trial with a novel ingenol derivative (ingenol disoxate: LEO 
43204) for field treatment of actinic keratosis on full face or 250 cm2 on the 
chest. J Dermatolog Treat. 2017:1-7. 
47. Shergill B, Zokaie S, Carr AJ. Non-adherence to topical treatments for actinic 
keratosis. Patient Prefer Adherence. 2013;8:35-41. 
48. Yentzer B, Hick J, Williams L, et al. Adherence to a topical regimen of 5-
fluorouracil, 0.5%, cream for the treatment of actinic keratoses. Arch Dermatol. 
2009;145(2):203-205. 




CHAPTER III: STUDY METHODS 
3.1 Study Design 
We will conduct a single-centered, intra-individual, single-blinded, randomized 
control trial.  The investigators will be blinded to the intervention, however, participants 
will not be blinded due to the nature of the study.  
 
3.2 Study Population and Sampling 
Our study population will be patients of the Dermatology Clinic at the West Haven 
VA.  A convenience sample of veterans aged 40 and above that meet the inclusion 
criteria will be chosen as participants.  
3.2.1 Inclusion Criteria 
Patients aged at least 40 with the presence of four to eight clinically typical, 
visible, and discrete AKs within a 25 cm2 contiguous field on the face or scalp. Female 
subjects must be of either non-childbearing potential, post-menopausal, or have a 
confirmed clinical history of sterility (e.g. hysterectomy).  Women must consent to using 
highly effective methods of contraception defined as abstinence, vasectomized partner, an 
intrauterine device, or oral contraceptives.  All patients must have the ability to follow 
trial instructions, and written informed consent must be obtained prior to any trial-related 
procedures. Subjects must allow photographs of the selected treatment area to be taken 
and used as part of the study data. 
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3.2.2 Exclusion Criteria 
Excluded patients will include those with recent transplantation or 
immunosuppression, other severe systemic infections, Olsen’s grade III AK and/or 
invasive tumors within the treatment area, recent use of medications or treatments that 
could interfere with study results (e.g., topical medications, artificial tanners, 
immunomodulating agents, cytotoxic drugs, UVB phototherapy, corticosteroids, or an 
oral retinoid), known allergies to any molecule in IMB or clobetasol propionate, 
pregnancy or lactation, prior topical treatment for AKs within a period of 6 months, 
likelihood of poor compliance, or an inability to fully consent to the study.  Areas within 
5 cm of an incompletely healed wound or within 10 cm of a suspected BCC or SCC will 
also be excluded.   
 
3.3 Subject Protection and Confidentiality 
This study will require approval by the Institutional Review Board (IRB) and 
Human Investigation Committee (HIC) at West Haven VA where subjects will be 
recruited and the study conducted (Appendix B).  In accordance with HIPPA Privacy 
Rule all participant records, photographs, and identifiers will be protected.  All patients 
will be assigned a unique code that will serve as their identifier throughout the course of 
this study and protect participant confidentiality.  All electronic records and patient 
information will be password protected and encrypted on computers.  Access to patient 
records will be provided to the dermatology team directly involved in the care of the 
patient.  Any physical records or paper consents will be stored in a locked cabinet at the 




Recruitment will be directed towards all veterans aged 40 and above who are patients 
in the dermatology clinic at the West Haven VA.  Recruitment flyers (Appendix C) will 
be posted in the dermatology clinic for patients.  A letter to the dermatologist team at the 
West Haven VA will be sent out asking for their participation in the study and their help 
in recruiting subjects (Appendix D).  Trained research personnel at the site will identify 
potential study participants established by their diagnosis of AK.  Consent for 
participation will be obtained before subjects get assessed for eligibility based on the 
inclusion criteria.   
 
3.5 Study Variables and Measures 
Two symmetrical contralateral areas of 25 cm2, harboring a similar (4-8) number of 
AKs, will be selected in an individual.  Through randomization these areas will get 
assigned monotherapy or combination therapy.  Randomization will be done using 
consecutively numbered, closed, nontransparent envelopes, which will contain a 
computer-generated allocation.   
The control for this study is monotherapy with 3 days of 0.015% IMB gel 
application to the allocated areas on the face or scalp.  The intervention for this study is 
0.05% clobetasol propionate ointment.  Patients will apply a thin application of 0.05% 
clobetasol propionate ointment to the assigned treatment area in addition to the standard 3 
days of 0.015% IMB gel.  They will wait 15 minutes after IMB application to apply the 
clobetasol propionate.  The first application of clobetasol propionate will be applied by 
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the researchers on day 0.  The intervention area will receive clobetasol propionate both 
before, during, and after 0.015% IMB gel therapy.  
The primary outcomes will be LSRs on day 4 and AK clearance efficacy on day 
57.  LSRs, which will be recorded quantitatively via photographic guides and a well-
defined LSR grading scale.  It will include erythema, flaking or scaling, crusting, 
swelling, vesiculation or pustulation, and erosion or ulceration.  The scale will range from 
0 to 4 with higher numbers indicating greater severity.  The mean composite LSR score 
will be the average of the composite LSR scores of the treated AKs and it will be 
recorded at each office visit.  AK clearance efficacy will be defined as more than 75% 
visual and dermoscopy clearance at day 57.   
Secondary outcomes will assess the long-term follow-up of AK clearance at 12 
months.  Application site pain (0-10) and pruritus (0-3) are commonly reported as 
adverse effects of IMB and will also be assessed from days 0-15.  Patients will record 
pain and pruritus using a VAS at home and they will also be asked about this during 
office visits (Appendix E).  
3.5.1 Blinding of Intervention  
 Investigators that are blinded to the treatment allocation will be assessing patients 
during follow-up office visits to determine their LSR scores.  Patients cannot be blinded 
because IMB therapy will induce LSR and according to our hypothesis clobetasol 
propionate will decrease inflammation on the treatment area.   
 43 
3.5.2 Assignment of Intervention 
 At the time of enrollment at least two symmetrical AK sites will be identified on 
the patient to undergo randomization.  Each patient will also receive a unique identifier 
code using a computer generated randomization program to de-identify their personal 
information.  A thin application of 0.05% clobetasol propionate ointment will be applied 
on the chosen AKs in office on day 0.  Patients will be given a 15g tube of 0.05% 
clobetasol propionate ointment to take home and continue application once a day until 
day 7.  Veterans will be provided with written instructions and treatment supplies 
required for the study (Appendix F).      
3.5.3 Adherence and Safety 
 Adherence will be monitored via self-administered patient medication logs 
(Appendix G).  Patients will also be verbally questioned about their medication 
compliance during clinic visits.  Patients will be reminded by investigators to administer 
appropriate clobetasol propionate and IMB doses at each appointment.  If major adverse 
effects occur as a result of corticosteroids or IMB, individual patient safety will be 
assessed to determine if the patient should continue the trial. 
 
3.6 Data Collection 
There will be two independent investigators that will evaluate the LSRs, take 




Initial Assessment: Day 0 
During office visits, patients will be identified by the residents working at the 
West Haven VA Dermatology Clinic.  During the initial assessment meeting patients will 
be given information about the research study and their eligibility for the study will be 
determined.  Researchers will review the patient’s electronic medical record to ensure 
they have not received topical treatment for their AKs in the past six months, and that 
they meet criteria for participation.  Once patients meet the inclusion and exclusion 
criteria they will have photographs taken of the AK lesions at baseline and then 
clobetasol propionate will be applied to the allocated area.  
 
Follow-up assessment: Day 1, 4, 7, 15, 57 and 12 months 
On day 1 patients will return for their first IMB application to both the control and 
treatment areas.  Researchers will demonstrate the proper application of IMB so patients 
can apply the product appropriately at home.  During each follow-up visit two blinded 
investigators will take photographs and conduct LSR assessment.  We will also review 
patient’s daily log of pain and pruritus and assess it again during office visits via the VAS 
method.  At day 57 overall lesion clearance will be dichotomized into PR (partial 
resolution of at least 75% visible or dermoscopy AKs) or NR (no resolution or resolution 
less than 75%).  We will study the long term efficacy of treatment by having the patients 











3.7 Sample Size Calculation 
Using the Power Analysis and Sample Size software we determined that using a two-
sided t-test with alpha=0.05, gives us a sample size of 34 (Appendix A).  This will 
provide us 80% power to detect a relative reduction in LSR score of 2.0 (SD 4.0), which 
corresponds to a 20% reduction after treatment.  Using McNemar’s test and the sample 
size of 34 patients, we will have 80% power to detect differences in paired proportions of 
26% - 34%.  To ensure adequate sample size, we will account for a 5% lost to follow-up, 













Day 7 Day 15 
Office Visits x x   x  x x 
Photographs x x   x  x x 
Informed Consent x        
Corticosteroid 
Application 
x x x x x x x  
Ingenol Mebutate 
Application 
 x x x     
Pain & Pruritus 
Measured 
x x x x x x x x 
 46 
3.8 Analysis 
The study will use intention-to-treat analysis with statistical significance 
considered for p-values < 0.05.  Primary outcomes such as the mean composite LSR 
scores will be assessed utilizing the quantitative scale created by Rosen et al.  AK 
clearance will be dichotomized into PR and NR.  Pain and pruritus will be measured 
using a VAS.  Wilcoxon signed-rank test will be used to analyze ordinal values such as 
LSR, pain, and pruritus.  McNemar’s test will be used to analyze dichotomous variables 
such as AK clearance.       
   
3.9 Timeline and Resources 
 Recruitment, randomization, data collection, and data analysis will be completed 
for this study within two years.  Recruitment period will begin January 2018 and will 
continue until October 2018.  Data collection and data analysis will be continuous during 
that period and this will allow us enough time to conduct a 12 month follow-up.  Due to 
the patient volume at the West Haven Dermatology Clinic we are not anticipating 
difficulty obtaining the 36 patients required for the study.   
The West Haven VA will have a designated primary investigator responsible for 
oversight of the trial.  The Principal Investigator of this study will be Dr. Suguru Imaeda 
and the Co-Principal Investigator will be Shreya Amin, PA-SII.  Two dermatology 
residents will be the researchers at the site and will be responsible for identifying and 
screening potential participants, obtaining informed consent, collecting baseline and 
follow-up data, and performing any additional tasks that may be required during the trial.  
Two separate, blinded residents will be the investigators responsible for evaluating LSR, 
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pain, and pruritus scores during each visit.  Data analysis can occur after eight weeks of 
treatment application and will continue until December 2020.  The Yale School of 




CHAPTER IV: CONCLUSION 
4.1 Advantages and Disadvantages 
There are a number of strengths to this proposed study design.  The intra-
individual study design is a great advantage because it minimizes confounding factors by 
allowing individuals to be compared only to themselves.  This prevents inter-patient 
variability in the response to IMB or corticosteroids.  Randomization of sites getting 
treatment allocation is determined by a computer, which prevents selection bias by the 
researchers.  
Conducting research at a single center, such as the West Haven VA, significantly 
limits the demographics of the population studied.  At the time of publication there are 
213,420 veterans living in the state of Connecticut, 60% of them are over the age of 60, 
88% of them are white, and 8% are female.1  However, fair-skinned males with high 
cumulative sun exposure are typically the patients that suffer from AKs so this is 
representative of the study population.  Thus, this should not affect the external validity 
of the study and its generalizability to patients suffering from widespread actinic damage.  
Also creating a single-centered study with a representative population prevents variability 
in the timing, delivery, and assessment of study interventions.  
Convenience sampling will ensure that there is enough study population, however 
because of high patient volume at the West Haven Dermatology Clinic starting the study 
in January may skew the number of patients recruited in the winter months and limit the 
number of patients in the summer.  Also, it is difficult to blind the subjects because of the 
nature of this study, which might result in subject bias.  However, the short duration of 
application time will most likely prevent any crossover from occurring.   
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A disadvantage of this intervention includes its complicated application course.  
IMB is favored over other field therapies because of its short treatment course of 3 days.  
Applying corticosteroid before and after IMB can provide additional treatment burden for 
patients that may end up reducing overall adherence. Non adherent patients, or those with 
minimal social support may be less willing to complete the study or follow-up at 12 
months after their lesions have resolved.  However, through proper patient education and 
explanation of the effectiveness of corticosteroids to reduce LSR and improve IMB 
tolerability, patients may be satisfied with the treatment.2  
Studies analyzing the impact of 0.015% IMB gel on the scalp have shown 
decreased efficacy and reduced LSR scores compared to the face.3,4 As a result, our study 
is analyzing combination therapy only on the face where LSRs are reported to be more 
adverse.  Excluding patients with scalp AKs is advantageous because it reduces potential 
confounders, however it limits the scope of our study.  Further research can investigate 
the effect of combination therapy specifically looking at scalp AKs.  
There are conflicting data about the effect of corticosteroids on IMB neutrophil-
mediated inflammation.  If combination therapy with a Class I corticosteroid, such as 
clobetasol propionate, has decreased efficacy compared to IMB alone at day 57 or month 
12, further studies can look at combination with a lower potency corticosteroid.  Previous 
research combining triamcinolone 0.5% cream and 5-fluorouracil demonstrated reduction 
of inflammation without impact on efficacy, so the impact of triamcinolone with IMB can 
also be investigated.   
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4.2 Clinical and/or Public Health Significance 
LSRs are common adverse effects reported in patients using IMB for the 
treatment of AKs.  Studies have shown LSR severity cannot be predicted before starting 
the treatment.  While corticosteroids have been successfully used to reduce erythema 
caused by other AK field therapies, there are limited studies analyzing its use with IMB.  
Currently more research needs to be conducted to investigate the role of concurrent 
clobetasol propionate application with IMB to reduce LSRs.  Studies have shown AK 
clearance improves with higher IMB concentrations.5  However, patients are hesitant to 
apply IMB with higher concentrations over large treatment areas as this induces more 
inflammation,6 which can potentially lead to increased cosmetic effects.  If this study can 
show the success of corticosteroids in reducing LSR without affecting efficacy, we can 
expand the role of IMB to areas greater than 25 cm2.  Providers can also prescribe higher 
concentrations without worrying about treatment safety and tolerability.  Additionally, for 
patients that suffer severe LSRs, pain, and pruritus using 0.015% IMB gel for face 
lesions, this combination therapy may provide significant relief, leading to improvement 
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APPENDIX B: HIC 
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
 
200 FR. 1 (2016-2)  
 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL: 
WEST HAVEN VETERANS AFFAIRS 
 
 
Study Title: Effect of Corticosteroid with Ingenol Mebutate on Local Skin Reaction for 
Actinic Keratosis Treatment  
Principal Investigator: Dr. Suguru Imaeda 
  
Invitation to Participate and Description of Project 
 
You are invited to participate in a research study designed to look at the ability of 
corticosteroids to reduce the adverse effects cause by actinic keratosis treatment by ingenol 
mebutate.  You have been asked to participate because you have been diagnosed with 
Grade I or II actinic keratoses, have not treated the lesions in the past 6 months, are above 
the age of 40, and are able to consent in English.  We will be recruiting approximately 36 
patients from the West Haven VA to participate in this study.  
 
In order to make an informed decision about whether or not you wish to participate 
in this research study we will review the risks and benefits of this study.  This consent form 
gives you detailed information about the research study, which a member of the research 
team will also discuss with you and answer any remaining questions you may have.  This 
discussion should go over all aspects of this research: its purpose, the procedures that will 
be performed, any risks of the procedures, and possible benefits.  Once you understand the 
study, you will be asked if you wish to participate; if so, you will be asked to sign this form. 
 
 
Description of Procedures 
 
If you agree to participate in this study, we will first obtain information about your previous 
actinic keratosis treatments to make sure that it doesn’t interfere with our study.  This may 
require us to obtain your medical information through your electronic medical record.  
  
Once deemed eligible, you will be asked to apply a thin layer of ingenol mebutate for 3 
days to the chosen lesions on the face and corticosteroid for 8 days to just the assigned 
treatment area.  A computer-generated allocation will indicate which AKs get assigned to 
combination therapy with clobetasol propionate treatment and ingenol mebutate and which 
ones get assigned to just the ingenol mebutate therapy. The first application of 
corticosteroid and the next application of both corticosteroid and ingenol mebutate will be 
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done in office.  After that the applications will be done by you at home and we will require 
you to fill out an adherence log to determine how you are applying the medication. 
 
 
In addition, you will need to return to the West Haven VA for follow-up visits at Day 1, 
Day 4, Week 8, and 12 months.  At each follow-up appointment you will bring your 
adherence log. You will be asked questions regarding your adherence, and photographs of 
the study sites will be taken.  You will also be asked to grade your pain and pruritus using 
a visual analog scale. 
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as 
required by U.S. Law. This Web site will include summary of the results, but will not 
have any information that can identify you.  You can search this Web site at any time. 
 
 
Risks and Inconveniences 
 
Risks of Clobetasol Propionate: 
 
Risks currently associated with topical corticosteroids are minimal and are listed below. 
 
• Central nervous system: Localized burning (5% to 40%), numbness of fingers 
(<2%), intracranial hypertension (children; systemic effect reported with topical 
corticosteroids) 
• Dermatologic: Stinging of skin (<2% to 5%), pruritus (<2% to 3%), eczema 
(pruritus hiemalis: 2%), xeroderma (≤2%), erythema (<2%), folliculitis (<2%), skin 
atrophy (<2%), skin fissure (<2%), telangiectasia (<2%), atrophic striae (children) 
• Endocrine & metabolic: Adrenal suppression, Cushing's syndrome, glycosuria, 
growth suppression, HPA-axis suppression, hyperglycemia 
• Local: Local irritation (1%), local pain (1%) 
• Respiratory: Upper respiratory tract infection (8%), nasopharyngitis (5%), 
streptococcal pharyngitis (1%) 
• Prevalence of positive contact allergy to topical corticosteroids is between 0.2% to 
6%.  Contact allergy is suspected in patients with worsening symptoms or lack of 
expected improvement in conditions otherwise responsive to topical 
corticosteroids.
 
Risks of Ingenol Mebutate: 
 
There is a greater than 10% risk of: 
 
• Dermatologic: Erythema (92% to 94%), desquamation (≤90%), exfoliation of skin 
(≤90%), crusted skin (74% to 80%), swelling of skin (face/scalp: 79%; 
trunk/extremities: 64%), localized vesiculation (face/scalp: ≤56%; 
trunk/extremities: ≤44%), pustules (face/scalp: ≤56%; trunk/extremities: ≤44%), 
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dermal ulcer (≤32%), skin erosion (≤32%), application site pain (face/scalp: 15%, 
trunk/extremities: 2%) 
 
Risk between 1% to 10%: 
• Central nervous system: Headache (face/scalp: 2%) 
• Dermatologic: Application site pruritus (8%), application site irritation 
(trunk/extremities: 4%), skin infection (face/scalp: 3%; at application site) 
• Ophthalmic: Periorbital edema (face/scalp: 3%) 
• Respiratory: Nasopharyngitis (trunk/extremities: 2%) 
 
Frequency not defined: 
• Ophthalmic: Conjunctivitis, eyelid edema, eye pain 
• According to a FDA Safety Alert on August 21, 2015 there have cases of 
anaphylaxis, conjunctivitis (chemical-induced), corneal injury (burn), eye injury, 
herpes zoster, pigmentation alteration (application site), scarring (application 
site), and severe hypersensitivity (includes allergic contact dermatitis) 
 
➢ Eye problems, including severe eye pain, swelling or drooping of your eyelids, 
corneal burn, redness, swelling and irritation inside the eye, or swelling around 
your eyes can happen if ingenol mebutate gel gets in your eyes. To avoid getting 
any of the ingenol mebutate gel into or around the eyes, it is important that you 
wash your hands well with soap and water after each application. If you 
accidentally get ingenol mebutate gel in your eyes, flush them with large amounts 





Benefits of this study include the potential improvement in local skin reactions and other 
side effects produced by the treatment of actinic keratosis with ingenol mebutate.  Since 
all patients will be receiving the standard of care, ingenol mebutate, clearance of actinic 
keratoses is expected to be seen in all participants.  We hope the results of this study will 





Thank you for your participation in this clinical trial.  While there is no financial 
incentive for your participation, all topical therapies used for this study will be provided 
to you free of charge.  All follow-up appointments will also be provided at no cost.  
However, please be aware that if you see a medical provider for other reasons than this 







Ingenol mebutate is currently a FDA approved first line field therapy for the treatment of 
actinic keratosis.  The current treatment options for lesion directed actinic keratosis 
include surgery, cryotherapy, dermabrasion.  Other field therapies for wide spread actinic 





Any identifiable information obtained for the study will remain confidential and will only 
be disclosed with your permission or as required by U.S. or State law.  Examples of 
information we are legally required to report includes abuse of a child or elderly person, 
or certain reportable diseases.  When you enroll in the study, a unique identifier code will 
be randomly assigned to you, and your name will not be used in the study or data 
analysis.   
 
All records with your information will be stored on encrypted, password protected 
computers.  Information about your study participation will be entered into your 
Computerized Patient Record System (CPRS). Once placed in your CPRS, these results 
are accessible to all of your providers who participate in the CPRS system. Information 
within your CPRS may also be shared with others who are appropriate to have access to 
your CPRS (e.g. health insurance company, disability provider.) 
 
Representatives from the Yale Human Research Protection Program, the Yale Human 
Investigation Committee (the committee that reviews, approves, and monitors research on 
human subjects) may inspect study records during internal auditing procedures.  However, 
these individuals are required to keep all information confidential.  
 
In addition, paper files that are generated will be stored in a locked cabinet and destroyed 
after the completion of the study.  You will have the right to view and request a copy of 
photographs taken during follow-up visits.  These will be erased after the completion of 
the study in 2 years.  When the results of the study are published, or discussed in 
conference, information about your identity will not be revealed until your consent if 
obtained.   
  
 
In Case of Injury 
 
West Haven Veterans Affairs does not provide funds for the treatment of research-related 
injury.  If you are injured as a result of your participation in this study, treatment will be 
provided.  You or your insurance carrier will be expected to pay the costs of this treatment.  
No additional financial compensation for injury or lost wages is available.  You do not give 
up any of your legal rights by signing this form. 
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Voluntary Participation and Withdrawal 
 
Participating in this study is voluntary and you are free to choose not to take part in this 
study.   Refusing to participate will not result in a penalty or loss of benefits to which you 
are otherwise entitled (such as your health care outside the study, the payment for your 
health care, and your health care benefits).  However, you will not be able to enroll in this 
research study or receive any of the treatment therapies.   
 
If you do become a subject, you are free to stop and withdraw from this study at any time 
during its course.  To withdraw from the study, you can call a member of the research 
team at any time and tell them that you no longer want to take part.  This will cancel any 
follow-up appointments.  
 
The researchers may withdraw you from participating in the research if necessary.  
Examples include becoming pregnant, developing a skin cancer near the site of research, 
any non-compliance to treatment, or experiencing severe side effects as a result of 
treatment.  
 
Withdrawing from the study will involve no penalty or loss of benefits to which you are 
otherwise entitled.  It will not harm your relationship with your own doctors or with any 
medical staff at the West Haven Veterans Affairs Medical Center.  
 
When you withdraw from the study, no new health information identifying you will be 
gathered after that date.  Information that has already been gathered may still be used and 
given to others until the end of the research study, as necessary to insure the integrity of 




We have used some technical terms in this form.  Please feel free to ask about 
anything you don't understand and to consider this research and the consent form carefully 





I have read (or someone has read to me) this form and have decided to participate in the 
project described above.  Its general purposes, the particulars of my involvement and 
possible hazards and inconveniences have been explained to my satisfaction.  My signature 
also indicates that I have received a copy of this consent form. 
 
 











Signature of Principal Investigator   Date 
  
                                      or 
 
___________________________________________ ___________________ 
Signature of Person Obtaining Consent   Date 
 
 
If you have further questions about this project or if you have a research-related problem, 
you may contact the Principal Investigator, Shreya Amin, 347-610-3803.  If, after you 
have signed this form you have any questions about your privacy rights, please contact 
the Yale Privacy Officer at 203-432-5919. If you would like to talk with someone other 
than the researchers to discuss problems, concerns, and questions you may have 
concerning this research, or to discuss your rights as a research subject, you may contact 




APPENDIX C: Patient Recruitment Flyer 
 
 61 
APPENDIX D: Letter to Dermatology Providers  
To the Dermatology Team at the West Haven VA: 
 
We are pleased to announce that we have recently received IRB approval to conduct an 
intra-individual randomized clinical trial to study the effect of corticosteroid with 
ingenol mebutate to reduce local skin reactions for actinic keratosis treatment.   
 
We are currently recruiting patients seen at the West Haven Dermatology Clinic to 
participate in this clinical trial.  Participation will be free and all medical treatments will 
be paid for in this study. 
 
To be considered patients must be: 
• Aged 40 or above with the presence of four to eight clinically typical, visible, and 
discrete actinic keratoses within a 25 cm2 contiguous field on the face.  
• Female subjects must be of either non-childbearing potential, post-menopausal, 
or have a confirmed clinical history of sterility (e.g. hysterectomy).  Women must 
be willing to consent to using high effective methods of contraception defined as 
abstinence, vasectomized partner, an intrauterine device, or oral contraceptives.   
• All patients must have the ability to follow trial instructions, agree to allow 
photographs to be taken as part of the study data analysis, and sign a written 
informed consent prior to any trial-related procedures.  
 
Exclusion Criteria for this trial includes: 
• Excluded patients will include those with recent transplantation or 
immunosuppression, other severe systemic infections, Olsen’s grade III AK 
and/or invasive tumors within the treatment area, known allergies to any 
molecule in IMB or corticosteroids, pregnancy or lactation, prior topical 
treatment for AK within a period of 6 months, likelihood of poor compliance, or 
an inability to fully consent to the study.  Areas within 5 cm of an incompletely 
healed wound or within 10 cm of a suspected BCC or SCC will also be excluded.    
 
If you or a team member encounters a patient in the dermatology clinic who might fit 
the criteria for our study, we would be very grateful if you could enroll them in the 
study.  Thank you for your help! 
  
        Sincerely, 
 
Shreya Amin, PA-SII 




APPENDIX E:  Patient VAS for Pain and Pruritus 
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APPENDIX F: Patient Instructions for Ingenol Mebutate and Corticosteroids  
Patient Instructions for Ingenol Mebutate and 
Clobetasol Propionate Usage 
 
 
Thank you for participating in this clinical research trial.  For the following 
8 days please follow these suggestions regarding medication application. 
 
Sunscreen Application: 
• Apply at least SPF 15 every day to the face  
• Wear protective clothing and use shade during peak sun hours from 
10am to 3pm  
 
Ingenol Mebutate Application: 
• Apply ingenol mebutate topically to the two chosen areas on the face 
using a total of six one unit-dose tubes for three days.  One unit-dose 
tube will cover ~5 cm x 5 cm (~25 cm2 or ~2 inch x 2 inch).  
• Spread evenly then allow gel to dry for 15 minutes  
• Do not cover with bandages or occlusive dressings  
• Wash hands immediately after applying and avoid transferring gel to 
any other areas 
• Avoid washing or touching the treatment area for at least 6 hours, and 
following this period of time, patients may wash the area with a mild 
soap. Not for oral, ophthalmic, or intravaginal use 
• Avoid application near or around the mouth, lips, or periocular areas 
 
Clobetasol Propionate Application: 
• Apply an even, thin coat of ointment only to the allocated treatment 
area on the face 15 minutes after ingenol mebutate application.   
• Once ingenol mebutate is discontinued continue corticosteroid 
application for four more days.   
• Do not cover with bandages or occlusive dressings 
• Wash hands immediately after applying and avoid transferring 
ointment to any other areas 
• Avoid application near or around the mouth, lips, or periocular areas 
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APPENDIX G: Patient Adherence Log 
 
Patient Medication Log     Patient ID:     
 





Day 1    
Day 2    
Day 3    
Day 4    
Day 5    
Day 6    
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